Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Sort By: Relevance
Journal Article
|Research
2023-06-06 • Lancet Microbe
2023-06-06 • Lancet Microbe
BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Journal Article
|Research
2023-02-21 • Open Forum Infectious Diseases
2023-02-21 • Open Forum Infectious Diseases
BACKGROUND
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...
Journal Article
|Letter
2022-10-01 • International Journal of Tuberculosis and Lung Disease
2022-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|Research
2014-04-01 • International Journal of Tuberculosis and Lung Disease
2014-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.
Journal Article
|Research
2015-11-10 • PLOS One
2015-11-10 • PLOS One
SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.
OBJECTIVE
To describe time to antiretroviral trea...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.
OBJECTIVE
To describe time to antiretroviral trea...
Journal Article
|Research
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|Letter
2021-05-01 • International Journal of Tuberculosis and Lung Disease
2021-05-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|Research
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|Research
2022-02-01 • International Journal of Tuberculosis and Lung Disease
2022-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Journal Article
|Case Report/Series
2021-05-01 • Pediatric Infectious Disease Journal
2021-05-01 • Pediatric Infectious Disease Journal
This brief report presents a series of 5 pregnant women treated for rifampicin-resistant tuberculosis with the novel drugs bedaquiline, delamanid, and linezolid as part of an optimized b...
Journal Article
|Research
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|Research
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|Research
2017-05-18 • PLOS One
2017-05-18 • PLOS One
BACKGROUND
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Journal Article
|Commentary
2022-03-01 • Lancet Respiratory Medicine
2022-03-01 • Lancet Respiratory Medicine
Journal Article
|Research
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|Research
2018-05-03 • European Respiratory Journal
2018-05-03 • European Respiratory Journal
Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was ...
Journal Article
|Research
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
Patients initiated on drug-resistant TB (DR-TB) treatment in 2019 in Khayelitsha, South Africa, with a loss to follow-up outcome were evaluated to better understand reasons for loss to f...
Journal Article
|Research
2017-10-01 • International Journal of Tuberculosis and Lung Disease
2017-10-01 • International Journal of Tuberculosis and Lung Disease
OBJECTIVE
To assess the proportion of rifampicin-resistant tuberculosis (RR-TB) patients with potential earlier RR-TB diagnoses in Khayelitsha, South Africa.
DESIGN
We c...
To assess the proportion of rifampicin-resistant tuberculosis (RR-TB) patients with potential earlier RR-TB diagnoses in Khayelitsha, South Africa.
DESIGN
We c...
Journal Article
|Letter
2020-07-01 • European Respiratory Journal
2020-07-01 • European Respiratory Journal
Journal Article
|Research
2021-10-18 • PLOS One
2021-10-18 • PLOS One
BACKGROUND
There are few data on the on post-treatment experiences of people who have been successfully treated for rifampicin-resistant (RR-)TB.
OBJECTIVE
To describe ...
There are few data on the on post-treatment experiences of people who have been successfully treated for rifampicin-resistant (RR-)TB.
OBJECTIVE
To describe ...